Rockefeller Capital Management L.P. Insmed Inc Transaction History

Rockefeller Capital Management L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Mar 06, 2023	BUY	$16.98 - $23.15 $5,212 - $7,107	307 Added 249.59%	430 $8,000
Q3 2022 Nov 02, 2022	SELL	$20.88 - $28.21 $13,947 - $18,844	-668 Reduced 84.45%	123 $2,000
Q2 2022 Aug 12, 2022	BUY	$17.07 - $25.71 $10,924 - $16,454	640 Added 423.84%	791 $15,000
Q1 2022 May 13, 2022	SELL	$20.42 - $28.13 $5,472 - $7,538	-268 Reduced 63.96%	151 $3,000
Q4 2021 Feb 14, 2022	SELL	$25.89 - $33.45 $27,987 - $36,159	-1,081 Reduced 72.07%	419 $11,000
Q3 2021 Nov 12, 2021	BUY	$22.46 - $29.47 $32,926 - $43,203	1,466 Added 4311.76%	1,500 $41,000
Q2 2021 Aug 10, 2021	BUY	$24.17 - $36.01 $821 - $1,224	34 New	34 $0
Q4 2020 Feb 12, 2021	SELL	$31.45 - $40.54 $4,686 - $6,040	-149 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$26.0 - $34.5 $1,456 - $1,932	56 Added 60.22%	149 $4,000
Q2 2020 Aug 12, 2020	SELL	$14.11 - $29.42 $747 - $1,559	-53 Reduced 36.3%	93 $3,000
Q1 2020 May 12, 2020	BUY	$13.63 - $33.98 $1,989 - $4,961	146 New	146 $2,000

467

182M

2.27M

3.33M

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.